PROMO Stock Overview
Promore Pharma AB (publ), a biopharmaceutical company, develops peptide-based drug candidates in Sweden and internationally.
Promore Pharma AB (publ) Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||kr1.06|
|52 Week High||kr2.00|
|52 Week Low||kr0.90|
|1 Month Change||-3.64%|
|3 Month Change||-6.19%|
|1 Year Change||-35.91%|
|3 Year Change||-77.92%|
|5 Year Change||-92.98%|
|Change since IPO||-92.35%|
Recent News & Updates
|PROMO||SE Biotechs||SE Market|
Return vs Industry: PROMO underperformed the Swedish Biotechs industry which returned -28.8% over the past year.
Return vs Market: PROMO underperformed the Swedish Market which returned -24.4% over the past year.
|PROMO Average Weekly Movement||11.3%|
|Biotechs Industry Average Movement||8.5%|
|Market Average Movement||7.0%|
|10% most volatile stocks in SE Market||11.5%|
|10% least volatile stocks in SE Market||4.3%|
Stable Share Price: PROMO is more volatile than 75% of Swedish stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: PROMO's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
Promore Pharma AB (publ), a biopharmaceutical company, develops peptide-based drug candidates in Sweden and internationally. Its product candidates include PXL01 that is in Phase IIa study for the prevention of post-surgical adhesions and scars, and for the prevention of dermal scars, as well as for tendon repair surgery in the hand; and LL-37, which is in Phase IIb clinical studies for treating patients with venous leg ulcers, stimulate the healing of chronic wounds, and for the treatment of diabetic foot ulcers. It entered into a cooperation agreement with Fidia Farmaceutici S.p.A. for the production of hyaluronic acid syringes.
Promore Pharma AB (publ) Fundamentals Summary
|PROMO fundamental statistics|
Is PROMO overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|PROMO income statement (TTM)|
|Cost of Revenue||kr15.18m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
Nov 29, 2022
|Earnings per share (EPS)||-0.43|
|Net Profit Margin||-5,470.48%|
How did PROMO perform over the long term?See historical performance and comparison